Lemairamin

Lemairamin, also referred to as WGX-50 or gx-50, is a small naturally occurring amide compound (chemically N-[2-(3,4-dimethoxyphenyl)ethyl]-3-phenyl-acrylamide) isolated from the pericarps of Zanthoxylum plants, the botanical source of Sichuan pepper ^[1][3]. It emerged from research into the bioactive constituents of this traditional culinary and medicinal spice and has attracted attention primarily as a candidate for neurodegenerative disease and cognitive support.

The compound's defining pharmacological feature is that it acts as an agonist of the alpha-7 nicotinic acetylcholine receptor (alpha-7 nAChR), a receptor that occupies a strategic position in the brain because it links the control of neuroinflammation with the cholinergic signaling involved in learning and memory ^[1][2]. In cellular and animal studies, lemairamin has reduced neuroinflammation and microglial activation, and in a transgenic Alzheimer's disease mouse model a preparation of the compound crossed the blood-brain barrier, decreased amyloid-beta accumulation, and improved cognitive performance ^[2][3].

Lemairamin is an early-stage research compound rather than an approved drug or an established supplement, and the bulk of its evidence comes from preclinical laboratory and animal work, so human clinical data are limited. It is typically encountered as a research chemical. Its interest lies in the combination of a natural origin, a well-defined molecular target relevant to both inflammation and cognition, and preclinical findings spanning pain, neuroinflammation, and Alzheimer's models ^[1][2][3].

Human safety is unknown, because no human has been studied. There are no adverse-event reports, no interaction data, no reproductive or genotoxicity testing, and no repeat-dose toxicology to any regulatory standard.

Regulatory status: not a controlled substance in the United States and not scheduled in any jurisdiction that could be confirmed; not an approved drug anywhere; no international nonproprietary name was found; not an authorised dietary-supplement ingredient. It is traded as a research chemical labelled not for human consumption. It does not appear on the WADA 2026 Prohibited List by name and does not fall inside a named class, but WADA section S0 prohibits at all times any pharmacological substance with no current approval by a governmental regulatory health authority for human therapeutic use, including compounds in preclinical development. Lemairamin meets that description, so a tested athlete should treat it as prohibited rather than as unlisted.

The animal data that exist are reassuring but thin. In mice, 28 mg/kg/day by gavage for four weeks, and 28 or 56 mg/kg/day for six weeks, produced no weight loss, no organ damage on histology of heart, liver, lung, spleen, kidney and intestine, and normal haematology plus normal ALT, AST, BUN and creatinine (PMID 41062925). Zebrafish embryo testing of the zanthoxylamide protoalkaloid series, which includes lemairamin, gave 96-hour LC50 values around 217 micromolar and classified the series as slightly toxic (PMID 30395926); that number describes the chemical series and was not measured for lemairamin alone.

Two mechanistic points warrant caution rather than comfort. An alpha-7 nicotinic agonist is an immune-modulating agent; the cholinergic anti-inflammatory pathway suppresses cytokine output, and the consequences of damping it chronically are unstudied. Separately, the compound suppresses ferroptosis and raises GPX4; that is protective against doxorubicin and radiation injury in the published models, but ferroptosis resistance is also a route by which tumour cells survive chemotherapy and radiotherapy, so anyone undergoing cancer treatment should not assume the effect is benign.

Lemairamin, also known by the research code WGX-50 or gx-50, is a bioactive amide isolated from the pericarps of Sichuan pepper plants of the genus Zanthoxylum, long used as a culinary spice in East Asia. Its emergence as a neuroscience compound is recent, driven largely by Chinese research groups, including teams at Shanghai Jiao Tong University, who identified it as a specific ligand of the alpha-7 nicotinic acetylcholine receptor.

Beginning in the 2010s, investigators reported that it could reduce amyloid-beta-induced neuroinflammation in microglia and improve cognitive measures in Alzheimer's disease models. A 2016 study mapped its anti-inflammatory action to activation of the JAK2/STAT3 and PI3K/AKT signaling pathways downstream of the alpha-7 receptor. A 2020 report extended its profile to pain, demonstrating antinociception through spinal alpha-7 receptors and the interleukin-10 and beta-endorphin pathways. Its documented history remains confined to preclinical laboratory research.

Lemairamin is viewed as an especially interesting botanically derived research compound, appealing precisely because its single molecular target sits at the intersection of two important processes. As an alpha-7 nicotinic receptor agonist it can both dampen neuroinflammation and engage circuitry central to memory, giving it a compelling dual rationale that has generated enthusiasm among researchers exploring neurodegeneration.

Preclinical data are genuinely encouraging, with reports that it reduces amyloid burden, protects neurons, and improves spatial memory in animal models, alongside a distinct antinociceptive effect. It is important to be candid that all of this evidence is preclinical; there are no human clinical trials, so its effects in people are unknown. For those drawn to the frontier of natural-product neuroscience, however, lemairamin remains a molecule of notable promise and elegant mechanism.